An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...

The going has been good for the German pharmaceutical giant Bayer BAYRY this year. Shares have surged 62.9% year to date ...

New York State Common Retirement Fund trimmed its Regeneron stake by 5% in Q1, selling over 6,800 shares worth millions.

The results position Hengrui to seek approval of the Zepbound-like drug in China, and Kailera, a well-funded startup, to ...

Following priority review, the U.S. Food and Drug Administration approved Bayer's Kerendia (finerenone) for the treatment of ...

The decision follows the initial approval granted in September 2023, which covered patients aged five years and above.

Leqselvi (deuruxolitinib) 8 mg tablets are approved for adults with severe alopecia areata, a disease that causes the immune system to attack hair follicles, leading to partial or complete hair loss ...

The FDA expanded the indication for finerenone (Kerendia) in heart failure (HF), drug manufacturer Bayer announced.

Kerendia was originally approved in July 2021 to reduce cardiovascular and kidney complications in patients with chronic ...

Finerenone gained FDA approval for heart failure treatment, showcasing significant benefits in reducing cardiovascular events ...

Wall Street’s major averages ended slightly lower last week, after posting back-to-back record closes as market participants juggled Trump's tariff announcements against a healthy appetite for ...

The hunt for a medical breakthrough has been caught up in the Trump administration's political assault on the university.